Imvax
PrivateLast Round
VC Round
Jan 29, 2025
Total Funding Raised
$175M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Imvax is a biotechnology company that develops patient-specific vaccines and immunotherapy strategies for the treatment of malignant gliomas and other solid tumor cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Imvax Comparables
Compare Imvax with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AiVita Biomedical | 83% | |
| IN8bio | 81% | |
| Diakonos Oncology | 81% |
Imvax Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Jan 29, 2025 | ||||
| VC Round | May 21, 2024 | ||||
| Series C Extension | Sep 6, 2023 | ||||
| Series C | Jul 16, 2020 | ||||
| Series B | May 1, 2019 | ||||
Series A | Jun 16, 2017 |
Imvax Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Benjamin Franklin Technology Partners | Series A |
| Magnetar Capital | Series C |
| Thomas Jefferson University | Series A |
| Invus Opportunities | Series C |
| TLP Investment Partners | Series C |
| TLP Invest | Series C |
| Ziff Capital Partners | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 111% MoM, reaching 3.4K.
- Jan 29, 2025
$29M round completed.
Recent news
Latest coverage and updates
- attends_eventSep 15, 2026
Imvax, Inc. has an abstract reporting results from its Phase 2b trial of IGV-001 in 99 patients with newly diagnosed glioblastoma accepted for poster and rapid oral presentation at the 31st Annual Meeting of the Society for Neuro-Oncology in Philadelphia, Pennsylvania, on Nov 12th-15th '26.
Imvax Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Imvax's valuation, stock price, and market status.
Is Imvax a public or private company?
Imvax is a private company.
What is the current stock price of Imvax?
Imvax is a private company, so its shares have no public market price. Caplight tracks Imvax's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Imvax worth (valuation)?
Valuation information for Imvax is not publicly available.
Can I buy Imvax stock?
Imvax shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Imvax's last funding round?
Imvax's most recent funding round was VC Round on January 29, 2025.
Who are the main investors in Imvax?
Key investors in Imvax include HP WILD HOLDING AG.
Will Imvax IPO soon?
No public IPO plans have been announced for Imvax.
How can I track Imvax secondary market activity?
Caplight tracks bids, offers, and trades in Imvax's shares on secondary markets.